about
Phosphodiesterase 4D regulates baseline sarcoplasmic reticulum Ca2+ release and cardiac contractility, independently of L-type Ca2+ currentUse of Inotropic Agents in Treatment of Systolic Heart FailureThe Role of Levosimendan in Patients with Decreased Left Ventricular Function Undergoing Cardiac SurgeryRegulation of phosphodiesterase 3 and inducible cAMP early repressor in the heartStructure and function of cardiac troponin C (TNNC1): Implications for heart failure, cardiomyopathies, and troponin modulating drugsInotropes do not increase mortality in advanced heart failureCardiac cyclic nucleotide phosphodiesterases: function, regulation, and therapeutic prospects.β2 adrenergic receptor activation governs cardiac repolarization and arrhythmogenesis in a guinea pig model of heart failureNew perspectives for the treatment of pulmonary hypertensionThe role of phosphodiesterase inhibitors in the management of pulmonary vascular diseasesStage-dependent benefits and risks of pimobendan in mice with genetic dilated cardiomyopathy and progressive heart failure.Rationale and design of the multicenter randomized trial investigating the effects of levosimendan pretreatment in patients with low ejection fraction (≤40 %) undergoing CABG with cardiopulmonary bypass (LICORN study).Selective regulation of cyclic nucleotide phosphodiesterase PDE3A isoforms.PDE3 inhibition in dilated cardiomyopathy.PDE3, but not PDE4, reduces β₁ - and β₂-adrenoceptor-mediated inotropic and lusitropic effects in failing ventricle from metoprolol-treated patients.Resveratrol enhances the inotropic effect but inhibits the proarrhythmic effect of sympathomimetic agents in rat myocardium.Functions of PDE3 Isoforms in Cardiac Muscle.Apremilast reversed carfilzomib-induced cardiotoxicity through inhibition of oxidative stress, NF-κB and MAPK signaling in rats.[Cyclic nucleotide phosphodiesterases: role in the heart and therapeutic perspectives].
P2860
Q24337525-E16B5F21-B111-4CC2-81B0-417113D21C7AQ26774435-8FD2E3C6-9845-40B1-AB50-C02C3B748445Q28075665-97191E59-26E1-4259-ADD0-DD904865C269Q28291007-9F945031-0CCB-4AC2-A298-4C3402417C6FQ28607749-A322BC68-A019-482F-8849-1E9FF35C20AAQ33685748-A0701FBA-8237-40AC-94E4-57B0D8B912B7Q33966155-11FE3D0C-C8B7-4C2B-AABE-36579C035693Q34865669-8A5C6095-9898-457D-B3DF-3EC70EA56D15Q34903204-45129FAC-2937-4CA1-951C-50E126588CCCQ35156618-6761E95D-AF98-4201-828F-B434230606FCQ35484468-6240B118-8D66-4E0C-85A2-D77A8E62A16DQ37154191-1738815D-E804-4F77-A4EE-541BC8733390Q37377525-B8D9D4AC-6BDD-4C3B-8166-A42BA49E3D3BQ37941174-0E2B4FE5-FBC6-472C-BB15-99DCC63B03C2Q42155457-4302C1FD-047B-4698-A776-38BAFF6B15B0Q42293112-8E1114D5-90BC-4AC5-B58A-FE0DC8467580Q50132075-19152A37-DC36-4BFD-B04D-31A4DCBB1224Q51360501-FE09D78C-7D13-4258-815F-14B70B0D87D1Q52969685-4EA203E6-9F1E-4BC2-A81F-5F6C707208ED
P2860
description
2005 nî lūn-bûn
@nan
2005 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Phosphodiesterase III inhibitors for heart failure
@ast
Phosphodiesterase III inhibitors for heart failure
@en
Phosphodiesterase III inhibitors for heart failure
@en-gb
Phosphodiesterase III inhibitors for heart failure
@nl
type
label
Phosphodiesterase III inhibitors for heart failure
@ast
Phosphodiesterase III inhibitors for heart failure
@en
Phosphodiesterase III inhibitors for heart failure
@en-gb
Phosphodiesterase III inhibitors for heart failure
@nl
prefLabel
Phosphodiesterase III inhibitors for heart failure
@ast
Phosphodiesterase III inhibitors for heart failure
@en
Phosphodiesterase III inhibitors for heart failure
@en-gb
Phosphodiesterase III inhibitors for heart failure
@nl
P2093
P2860
P3181
P1476
Phosphodiesterase III inhibitors for heart failure
@en
P2093
Christelle Kasparian
Emmanuel Amsallem
Jean-Pierre Boissel
Patrice Nony
P2860
P3181
P356
10.1002/14651858.CD002230.PUB2
P577
2005-01-24T00:00:00Z